<DOC>
	<DOCNO>NCT02521311</DOCNO>
	<brief_summary>The main purpose study assess clemastine remyelinating agent patient acute optic neuritis.The study also evaluate tolerability clemastine , originally approve first-generation antihistamine , patient optic neuritis . Study procedure include assessment evidence remyelination anterior visual pathway brain use electrophysiologic technique magnetic resonance imaging . If one , patient study remain standard disease modify treatment course study . However , patient participate investigational new drug research study concurrently .</brief_summary>
	<brief_title>Assessment Clemastine Fumarate Remyelinating Agent Acute Optic Neuritis ( ReCOVER )</brief_title>
	<detailed_description />
	<mesh_term>Optic Neuritis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<mesh_term>Clemastine</mesh_term>
	<criteria>Patients diagnose suspected acute demyelinate optic neuritis least one eye within 2 week onset visual symptom pain Use disease modify therapy contraindication Use appropriate contraception period trial ( woman ) Understand sign informed consent Other major ophthalmologic disease / concomitant ophthalmologic disorder ( e.g . diabetes , macular degeneration , glaucoma , severe myopia , etc ) Disc hemorrhage qualify eye No light perception qualify eye Simultaneous bilateral optic neuritis Cotton wool spot qualify eye Macular star qualify eye History significant cardiac conduction block History cancer Suicidal ideation behavior 6 month prior baseline Pregnancy , breastfeeding , plan become pregnant Involved study protocol simultaneously without prior approval Concomitant use putative remyelinating therapy determine investigator Serum creatinine &gt; 1.5 mg/dL ; aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , alkaline phosphatase &gt; 2 time upper limit normal History drug alcohol abuse within past year Untreated B12 deficiency ( determine B12 serological assessment metabolites include methylmalonic acid ( MMA ) homocysteine ) untreated hypothyroidism Clinically significant cardiac , metabolic , hematologic , hepatic , immunologic , urologic , endocrinologic , neurologic , pulmonary , psychiatric , dermatologic , allergic , renal , major disease , PI 's judgment , may affect interpretation study result patient safety History presence clinically significant medical illness laboratory abnormality , opinion investigator would preclude participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>eye pain</keyword>
	<keyword>vision loss</keyword>
</DOC>